Regenxbio looks to partner neurodegenerative gene therapy work, lays off 15% of staff
Regenxbio has laid off 15% of its staff as it narrows down its pipeline to focus on three gene therapy programs.
The Rockville, MD-based biotech has about 400 employees, according to remarks made by president and CEO Ken Mills at an investor conference in September. That means approximately 60 staffers were laid off.
Regenxbio said Wednesday that the workers who are being let go primarily work in neurodegenerative disease development, early research and other general and administrative areas. The company declined to share specific numbers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
